- For investors considering whether Biogen’s share price reflects its underlying value, the recent mix of long term gains and shorter term pullbacks makes the valuation question especially relevant.
- The stock closed at US$180.67, with returns of 51.7% over the past year. Over shorter periods, the share price has been more volatile, with 7 day and 30 day moves of 1.5% and 1.7% declines, and a 1.6% gain year to date.
- Recent attention on Biogen has centered on its core neurology franchise and pipeline decisions. These factors can influence how investors weigh potential future revenue against current pricing. This context helps explain why the share price picture looks different when comparing the last year with the past 3 and 5 years, which…
Passive strategies now riskier than ever
April 28, 2026
